The global erectile dysfunction (ED) drugs market to reach a value of US$ 2.79 Bn by the end of 2026 is expected to decline with 3.2% CAGR over the forecast period from 2019 to 2026.
The report analyzes and forecasts the erectile dysfunction (ED) drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of erectile dysfunction (ED) drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major erectile dysfunction (ED) drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of erectile dysfunction (ED) drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of erectile dysfunction (ED) drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global erectile dysfunction (ED) drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the erectile dysfunction (ED) drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of erectile dysfunction (ED) drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Major players operating in the global erectile dysfunction drugs market are Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, VIVUS, Inc., SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Teva Pharmaceutical Industries Ltd.
The global erectile dysfunction drugs market has been segmented as follows:
Global Erectile Dysfunction Drugs Market, By Drug
Global Erectile Dysfunction Drugs Market, By Distribution Channel
Global Erectile Dysfunction Drugs Market, By Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights
2. Assumptions and Research Methodology
2.1. Secondary Research Methodology
2.2. Primary Research Methodology
2.3. Analysis Research Methodology
3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
5. Market Outlook
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunity
5.1.4. Opportunity Analysis
5.1.5. Trends
5.2. Global Erectile Dysfunction Market Analysis and Forecasts, 2017–2026
5.3. Porter’s Five Forces Analysis
5.4. Erectile Dysfunction Drugs Market Value Chain Analysis
5.5. Pipeline Analysis
5.5.1. Discovery
5.5.2. Preclinical
5.5.3. IND (Investigational New Drug)
5.5.4. Phase I
5.5.5. Phase I/II
5.5.6. Phase II
5.5.7. Phase III
5.5.8. Pre-registration
5.6. Global Erectile Dysfunction (ED) Drug Market Outlook
6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Drug
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug, 2017–2026
6.3.1. Viagra
6.3.2. Cialis
6.3.3. Staxyn/Levitra
6.3.4. Stendra/Spedra
6.3.5. Others
6.4. Market Attractiveness, by Drug
7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2026
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Market Attractiveness, by Distribution Channel
8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug, 2017–2026
9.2.1. Viagra
9.2.2. Cialis
9.2.3. Staxyn/Levitra
9.2.4. Stendra/Spedra
9.2.5. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2026
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Value Forecast, by Country, 2017–2026
9.4.1. U.S.
9.4.2. Canada
10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug, 2017–2026
10.2.1. Viagra
10.2.2. Cialis
10.2.3. Staxyn/Levitra
10.2.4. Stendra/Spedra
10.2.5. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2026
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Market Value Forecast, by Country/Sub-region, 2017–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Drug, 2017–2026
11.2.1. Viagra
11.2.2. Cialis
11.2.3. Staxyn/Levitra
11.2.4. Stendra/Spedra
11.2.5. Others
11.3.Market Value Forecast, by Distribution Channel, 2017–2026
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4.Market Value Forecast, by Country/Sub-region, 2017–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Drug, 2017–2026
12.2.1. Viagra
12.2.2. Cialis
12.2.3. Staxyn/Levitra
12.2.4. Stendra/Spedra
12.2.5. Others
12.3.Market Value Forecast, by Distribution Channel, 2017–2026
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4.Market Value Forecast, by Country/Sub-region, 2017–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Drug, 2017–2026
13.2.1. Viagra
13.2.2. Cialis
13.2.3. Staxyn/Levitra
13.2.4. Stendra/Spedra
13.2.5. Others
13.3.Market Value Forecast, by Distribution Channel, 2017–2026
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4.Market Value Forecast, by Country/Sub-region, 2017–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2018)
14.3. Competitive Business Strategies
14.4. Company Profiles
14.4.1. Pfizer, Inc.
14.4.1.1. Company Overview (HQ, Business Segments, Employee)
14.4.1.2. Product Portfolio
14.4.1.3. SWOT Analysis
14.4.1.4. Strategic Overview
14.4.2. Dong-A ST Co., Ltd.
14.4.2.1. Company Overview (HQ, Business Segments, Employee)
14.4.2.2. Product Portfolio
14.4.2.3. SWOT Analysis
14.4.2.4. Strategic Overview
14.4.3. Eli Lilly and Company
14.4.3.1. Company Overview (HQ, Business Segments, Employee)
14.4.3.2. Product Portfolio
14.4.3.3. SWOT Analysis
14.4.3.4. Strategic Overview
14.4.4. Bayer AG
14.4.4.1. Company Overview (HQ, Business Segments, Employee)
14.4.4.2. Product Portfolio
14.4.4.3. SWOT Analysis
14.4.4.4. Strategic Overview
14.4.5. VIVUS, INC.
14.4.5.1. Company Overview (HQ, Business Segments, Employee)
14.4.5.2. Product Portfolio
14.4.5.3. SWOT Analysis
14.4.5.4. Strategic Overview
14.4.6. SK chemicals
14.4.6.1. Company Overview (HQ, Business Segments, Employee)
14.4.6.2. Product Portfolio
14.4.6.3. SWOT Analysis
14.4.6.4. Strategic Overview
14.4.7. Meda Pharmaceuticals Inc.
14.4.7.1. Company Overview (HQ, Business Segments, Employee)
14.4.7.2. Product Portfolio
14.4.7.3. SWOT Analysis
14.4.7.4. Strategic Overview
14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.
14.4.8.1. Company Overview (HQ, Business Segments, Employee)
14.4.8.2. Product Portfolio
14.4.8.3. SWOT Analysis
14.4.8.4. Strategic Overview
14.4.9. Apricus Biosciences, Inc.
14.4.9.1. Company Overview (HQ, Business Segments, Employee)
14.4.9.2. Product Portfolio
14.4.9.3. SWOT Analysis
14.4.9.4. Strategic Overview
14.4.10. Teva Pharmaceutical Industries Ltd.
14.4.10.1. Company Overview (HQ, Business Segments, Employee)
14.4.10.2. Product Portfolio
14.4.10.3. SWOT Analysis
14.4.10.4. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers